Table 11A:
Fibroid-Related Symptom Reduction With Restricted MRgHIFU Ablation Protocols
| Country, Site, Author, Year | Study Size, N | Symptom Measures | Symptom Reduction at Follow-Up Points | |||||
|---|---|---|---|---|---|---|---|---|
| Baseline | 3 months | 6 months | 12 months | 24 months | 36 months | |||
| Korea, CHA Bundang Medical Center, Yoon S-W et al, 2013 (111) | 60 | UFS-QOL (SSS) Mean ± SD | 50 ± 22 | 33 ± 16 P < 0.0001 | NR | 19 ± 12 P < 0.0001 | ||
| Korea, Samsung Medical Center, Park M et al, 2013 (89) | 43 | UFS-QOL (SSS) Mean ± SD (range) | 43 ± 18 (9–81) | 26 ± 12 (6–50) P < 0.001 | ||||
| Netherlands, University Medical Center, Utrecht, Ikink M et al, 2013 (112) | 46 | UFS-QOL (SSS) Mean ± SD (range) | 51 ± 18 | NR | 35 ± 20 P < 0.001 | |||
| United States Mayo Clinic, Hesley G et al 2006 (93) | 42 | Self-reported symptom improvement | See summary in text | |||||
| United States, MCT, Fennessy F et al, 2007 (49) | 160 | UFS-QOL (SSS) Mean ± SD (range) | 62 ± 16 | 36 ± 20 P < 0.001 | 33 ± 20 P < 0.001 | 33 ± 21 P < 0.001 | ||
| United States, Johns Hopkins University School of Medicine, Kim H et al, 2011 (114) | 40 | UFS-QOL (SSS) Mean (95% CI) | 65 (59–71) | 35 (29–41) | 32 (26–38) | 41 (33–49) | 18 (8–28) | 17 (9–25) |
| United States, Brigham and Women's Hospital, Lenard Z et al, 2008 (113) | 66 | UFS-QOL (SSS) Mean ± SD | 62 ± 15 | NR | 34 ± 17 | 38 ± 18 P < 0.001 | ||
| United States, MCT, Machtinger R et al, 2013 (107) | 63 (AA) | UFS-QOL (SSS) Median (IQR) | 69 (50–81) | NR | NR | 33 (13–47) P < 0.0001 | 28 (9–44) | 13 (6–38) |
| 59 (Non-AA) | UFS-QOL (SSS) Median (IQR) | 59 (50–78) | NR | NR | 31 (19–44) P < 0.0001 | 27 (9–44) | 19 (13–41) | |
| United States, Brigham and Women's Hospital (MCT), Stewart E et al, 2006 (110) | 176 | UFS-QOL (SSS) Mean ± SD | 62 ± 15 | 41 ± 22 P < 0.001 | 38 ± 21 P < 0.001 | |||
Abbreviations: AA, African-American; CI, confidence interval; IQR, inter-quartile range; MCT, multicentre trial; MRgHIFU, magnetic resonance–guided high-intensity focused ultrasound; NR, not reported; SD, standard deviation; SSS; symptom severity score; UFS-QOL, Uterine Fibroid Symptom and Quality of Life questionnaire.